Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence.
Saved in:
| Title: | Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence. |
|---|---|
| Authors: | Varco-Merth B; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Chaunzwa M; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Duell DM; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Marenco A; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Goodwin W; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Dannay R; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Nekorchuk M; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Shao D; Fred Hutchinson Cancer Research Center, Seattle, Washington State, United States of America., Busman-Sahay K; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Fennessey CM; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Silipino L; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Hull M; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Bosche WJ; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Fast R; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Oswald K; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Shoemaker R; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Bochart R; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., MacAllister R; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Labriola CS; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Smedley JV; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Axthelm MK; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Davenport MP; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia., Edlefsen PT; Fred Hutchinson Cancer Research Center, Seattle, Washington State, United States of America., Estes JD; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Keele BF; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Lifson JD; AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America., Lewin SR; Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.; Victorian Infectious Diseases Service, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia., Picker LJ; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America., Okoye AA; Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.; Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2024 Aug 22; Vol. 20 (8), pp. e1012496. Date of Electronic Publication: 2024 Aug 22 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
